Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1201

REGN7075-hIgG4

Home » REGN7075-hIgG4

Background of REGN7075-hIgG4

    REGN7075-is-a-novel-costimulatory-bispecific-antibody-(bsAb)-designed-to-enhance-anti-tumor-immune-responses-by-bridging-epidermal-growth-factor-receptor-(EGFR)-expressing-tumor-cells-with-CD28-positive-T-cells.-This-mechanism-aims-to-activate-T-cells-within-the-tumor-microenvironment,-potentially-turning-"cold"-tumors-into-"hot"-ones,-thereby-increasing-their-responsiveness-to-immunotherapy.

Specifications

Catalog Number:
KB-1201
Antibody Name:
REGN7075-hIgG4
Isotype:
FC Muations:
S228P
Target:
EGFR&CD28
Species Reactivity:
Host Cell Line:
EXPICHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. 1.-A-phase-1/2-study-of-REGN7075-in-combination-with-cemiplimab-(cemi)-in-patients-(pts)-with-advanced-solid-tumors:-Efficacy-and-safety-results.